rabbit anti-thymocyte globulin + tacrolimus + mycophenolate mofetil

This is a combination immunosuppressive regimen consisting of three agents: **rabbit anti-thymocyte globulin (ATG)**, **tacrolimus**, and **mycophenolate mofetil**. - **Rabbit anti-thymocyte globulin (ATG)** is a polyclonal antibody preparation from rabbits immunized with human thymocytes, resulting in potent depletion of T lymphocytes and broad immunosuppression, used especially for preventing graft rejection and graft-versus-host disease (GVHD) in transplantation settings[1][3][7]. - **Tacrolimus** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting IL-2 transcription, also used widely for organ transplant rejection prophylaxis[1][3][5][7]. - **Mycophenolate mofetil** is a prodrug for mycophenolic acid, a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), decreasing lymphocyte proliferation by blocking de novo guanosine synthesis; it is also used for transplant rejection prevention and some autoimmune diseases[2][4][6]. This regimen is primarily used for prevention of acute and chronic graft-versus-host disease (GVHD), especially in the setting of **allogeneic stem cell transplantation** from unrelated donors, and in some protocols for solid organ transplant (e.g., liver) where steroid-free regimens are desired[1][3][5][7]. The combination exploits ATG's lymphocyte-depleting effects, tacrolimus's calcineurin inhibition, and mycophenolate's anti-proliferative action to provide synergistic immunosuppression[1][3][5][7].

Other names

ATG + MMF + TacrolimusTriple immunosuppression protocolATG-Fresenius + CellCept + Prograf